Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 2, 2023

Investigational Drug Information for Tegobuvir

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the drug development status for Tegobuvir?

Tegobuvir is an investigational drug.

There have been 5 clinical trials for Tegobuvir. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1^st 2011.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].

Summary for Tegobuvir

US Patents	0
International Patents	0
US Patent Applications	280
WIPO Patent Applications	192
Japanese Patent Applications	102
Clinical Trial Progress	Phase 2 (2011-09-01)
Vendors	48

Recent Clinical Trials for Tegobuvir

Title	Sponsor	Phase
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection	Gilead Sciences	Phase 2
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection	Gilead Sciences	Phase 2
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection	Gilead Sciences	Phase 2

See all Tegobuvir clinical trials

Clinical Trial Summary for Tegobuvir

Top disease conditions for Tegobuvir

Top clinical trial sponsors for Tegobuvir

See all Tegobuvir clinical trials

US Patents for Tegobuvir

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign up for a Free Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

McKesson

Moodys

Colorcon

Medtronic

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.